ID
21939
Beskrivning
This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease. GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00381238?term=NCT00381238&rank=1
Länk
https://clinicaltrials.gov/ct2/show/NCT00381238?term=NCT00381238&rank=1
Nyckelord
Versioner (2)
- 2017-05-09 2017-05-09 -
- 2017-05-22 2017-05-22 -
Uppladdad den
9 maj 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Investigational Product Visit 1 (Week 0) Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease NCT00381238
Laboratory Data Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease NCT00381238
Beskrivning
Compliance
Alias
- UMLS CUI-1
- C1321605
Beskrivning
Treatment Confirmation
Alias
- UMLS CUI-1
- C0750484
- UMLS CUI-2
- C0087111
Similar models
Laboratory Data Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease NCT00381238
C0039225 (UMLS CUI [1,2])
C0039225 (UMLS CUI [1,2])
C0087111 (UMLS CUI-2)